Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

This study has been completed.
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: December 1, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Condition Intervention Phase
Vogt Koyanagi Harada Disease
Serpiginous Choroiditis
Multifocal Choroiditis
Drug: Bevacizumab
Procedure: Intravitreal Injection of Bevacizumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Best corrected visual acuity
  • Retinal thickness by OCT
  • Leakage in Fluorescein angiogram

Study Start Date: August 2006
Estimated Study Completion Date: November 2006

Ages Eligible for Study:   25 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical Diagnose
  • Patient Consent
  • Chronic stage of inflammation

Exclusion Criteria:

  • only eye
  • age lower than 30 yo.
  • Systemic condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00407121

Asociacion para Evitar la Ceguera en Mexico
Mexico, Distrito Federal, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Veronica Kon-Jara, MD Asociación para Evitar la Ceguera en México
Study Chair: LuzElena Concha-Del Rio, MD Asociación para Evitar la Ceguera en México
  More Information

No publications provided Identifier: NCT00407121     History of Changes
Other Study ID Numbers: APEC-0025
Study First Received: December 1, 2006
Last Updated: December 1, 2006
Health Authority: National Institute of Public Health: Health Secretariat

Keywords provided by Asociación para Evitar la Ceguera en México:
Neovascular Membrane

Additional relevant MeSH terms:
Uveomeningoencephalitic Syndrome
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Central Nervous System Diseases
Central Nervous System Infections
Choroid Diseases
Eye Diseases
Immune System Diseases
Nervous System Diseases
Uveal Diseases
Uveitis, Posterior
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2015